SWEDISH ORPHAN BIOVIT.SK1
SWEDISH ORPHAN BIOVIT.SK1/ SE0000872095 /
B6E
|
03/06/2024 08:08:14
|
Chg.
+0.680
|
Volume |
Bid18:07:04 |
Demandez à18:07:04 |
Capitalisation boursière |
Dividende Y. |
Rapport P/E |
|
24.820EUR
|
+2.82%
|
0
Chiffrre d'affaires: 0.000 |
24.800Bid taille: 170 |
25.020Ask la taille: 160 |
8.74 Mrd.EUR |
- |
- |
Description de l'entreprise
Swedish Orphan Biovitrum AB is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the lives of rare disease patients and their families.
Conseil d'administration & Conseil de surveillance
| PDG |
| Guido Oelkers |
| Conseil d'administration |
| Henrik Stenqvist, Lydia Abad-Franch, Duane H. Barnes, Lena Bjurner, Sofiane Fahmy, Torbjörn Hallberg, Mahmood Ladha, Norbert Oppitz, Daniel Rankin, Armin Reininger, Christine Wesström |
| Conseil de surveillance |
| Annette Clancy, Christophe Bourdon, Helena Saxon, Staffan Schüberg, Katy Mazibuko, Mats Lek, Anders Ullman, Filippa Stenberg |
Données de l'entreprise
| Nom: |
Swedish Orphan Biovitrum AB |
| Adresse: |
Tomtebodavägen 23A,Solna 112 76 |
| Téléphone: |
+46-8-697-2000 |
| Fax: |
- |
| Courriel: |
-
|
| Internet: |
www.sobi.com |
| Industrie: |
Biotechnology |
| Secteur: |
Biotechnology |
| Sous-secteur: |
Biotechnology |
| Fin de l'exercice financier: |
31/12 |
| Flotte libre: |
42.16% |
| IPO date: |
- |
Calendrier de l'entreprise
|
CW 29 | 16/07/2024
Interim Report 2nd Quarter/6 Months
|
|
CW 43 | 24/10/2024
Interim Report 3rd Quarter/9 Months
|
